This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

AACR 2019

American Association for Cancer Research Congress 2019

At the AACR annual meeting, Boehringer Ingelheim displayed their cutting-edge scientific discoveries in cancer cell- and immune cell-directed agents.

29 March–3 April 2019
Georgia World Congress Center, Atlanta, Georgia, United States
Publications
Filter by:
Presentation Type
  • All presentation types
  • Oral Presentation
  • Poster Presentation
  • e-Presentation
Tumour Type
  • All tumour types

Boehringer Ingelheim presented several publications during the scientific program at AACR – discover our data by exploring these below.

Sunday 31st March 2019
BI 905677*, a first-in-class LRP5/6 antagonist targeting Wnt-driven proliferation and immune escape
Author(s): Zinzalla et al.
Oral Presentation
Tumour Type(s): N/A
Presentation Number: DDT01-01
SMARCA4 is a selective vulnerability in SMARCA2-deficient esophageal squamous cell carcinoma cell lines
Author(s): Ehrenhöfer-Wölfer et al.
Poster Presentation
Tumour Type(s): N/A
Presentation Number: 397 / 29
Selective and potent CDK8 inhibitors enhance NK cell activity and promote tumor surveillance
Author(s): Hofmann et al.
Poster Presentation
Tumour Type(s): N/A
Presentation Number: 510 / 9
A novel T cell engaging bispecific antibody induces specific and efficacious lysis of small cell lung cancer cells in vitro and potent T cell re-directed anti-tumor activity in vivo
Author(s): Hipp et al.
Poster Presentation
Tumour Type(s): SCLC
Presentation Number: 549 / 13
There are no publications which meet your criteria on this date
Monday 1st April 2019
BI 905711*, a novel CDH17-targeting TRAILR2 agonist, effectively triggers tumor cell apoptosis and tumor regressions selectively in CDH17-positive colorectal cancer models
Author(s): Garcia-Martinez et al.
Poster Presentation
Tumour Type(s): N/A
Presentation Number: 2051 / 3
Therapeutic synergy of the chimeric, oncolytic virus VSV-GP with immune modulators
Author(s): Müller et al.
Poster Presentation
Tumour Type(s): N/A
Presentation Number: 2267 / 26
Werner syndrome helicase is a selective vulnerability of microsatellite instability-high tumor cells
Author(s): Lieb et al.
Poster Presentation
Tumour Type(s): N/A
Presentation Number: 2560 / 4
There are no publications which meet your criteria on this date
Tuesday 2nd April 2019
Structure-based PROTAC design demonstrates BAF complex ATPase vulnerabilities in cancer
Author(s): Kögl et al.
Poster Presentation
Tumour Type(s): N/A
Presentation Number: 3849 / 24
Predicting MCL1 inhibitor sensitivity in large cell line panels using a gene expression signature
Author(s): Wernitznig et al.
Poster Presentation
Tumour Type(s): N/A
Presentation Number: 3987 / 13
BI 907828*, a novel and potent MDM2-p53 antagonist, acts synergistically in a triple combination with anti-PD-1 and anti-LAG-3 antibodies in syngeneic mouse models of cancer
Author(s): Rudolph et al.
Poster Presentation
Tumour Type(s): N/A
Presentation Number: 3197 / 7
BI 907828*: a novel, potent MDM2 inhibitor, inhibits GBM brain tumor stem cells in vitro and prolonged survival in orthotopic xenograft mouse models
Author(s): Luchman et al.
Poster Presentation
Tumour Type(s): N/A
Presentation Number: 3084 / 18
Distinct immune stimulatory functions of anti-human VISTA antibodies are determined by the antibody isotype
Author(s): Mostböck et al.
Poster Presentation
Tumour Type(s): N/A
Presentation Number: 3266 / 16
There are no publications which meet your criteria on this date
Wednesday 3rd April 2019
Epigenomic and transcriptional profiling of CRC cell lines with distinct response patterns to the BET inhibitor BI 894999*
Author(s): Savarese et al.
Poster Presentation
Tumour Type(s): N/A
Presentation Number: 5194 / 12
There are no publications which meet your criteria on this date

Find out more about other oncology events

Click here to find out more about other oncology meetings, congresses, symposia and activities sponsored by Boehringer Ingelheim.

 

*These are investigational compounds and have not been approved. Their safety and efficacy have not been established.

 

© 2019 Boehringer Ingelheim International GmbH. All rights reserved.

 

Page last updated: April 2019